Editorial Board About Us

Tumor markers

All articles from this key word are listed below.

Volume 2, Supplement 4 Supplement

Serum and Tissue Markers for Prostate Cancer

Serum and Tissue Markers for Prostate Cancer

Michael K Brawer Martin I Resnick Martin E Gleave Hans Lilja Nelson Neal Stone

Prostatic neoplasms Prostate-specific antigen Tumor markers Sensitivity and specificity

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

John P Mulhall John P Stein Arie S Belldegrun Tobias Klatte Michael E Aldridge Li-Ming Su Shachi Tyagi Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor Victor W Nitti J Curtis Nickel Jacob Rajfer Claus G Roehrborn Michael K Brawer

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 10, Number 2 Review Articles

Critical Evaluation of Urinary Markers for Bladder Cancer Detection and Monitoring

Diagnostic Update

Jose A Karam Pierre I Karakiewizc Shahrokh F Shariat Yair Lotan

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has high specificity but low sensitivity for low-grade bladder tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Although several markers have been approved by the US Food and Drug Administration for bladder cancer surveillance, only a few are approved for detection of bladder cancer in high-risk patients. [Rev Urol. 2008;10(2):120-135]

Bladder cancer Tumor markers Cystoscopy Urine cytology

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

F Pouliot B Shuch Arie S Belldegrun Naoki Yoshimura Stacy Loeb Ellen Shapiro Alan W Partin Michael B Chancellor Dean G Assimos J Curtis Nickel Claus G Roehrborn Michael K Brawer

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery